A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies
The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work was to develop a mechanistic whole-body physiolo...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
16 June 2020
|
| In: |
Pharmaceutics
Year: 2020, Jahrgang: 12, Heft: 6, Pages: 556 |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics12060556 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/pharmaceutics12060556 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4923/12/6/556 
|
| Verfasserangaben: | Nina Hanke, Denise Türk, Dominik Selzer, Sabrina Wiebe, Éric Fernandez, Peter Stopfer, Valerie Nock and Thorsten Lehr |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1735274143 | ||
| 003 | DE-627 | ||
| 005 | 20241227233958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201009s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics12060556 |2 doi | |
| 035 | |a (DE-627)1735274143 | ||
| 035 | |a (DE-599)KXP1735274143 | ||
| 035 | |a (OCoLC)1341370848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 30 |2 sdnb | ||
| 100 | 1 | |a Hanke, Nina |d 1976- |e VerfasserIn |0 (DE-588)130425133 |0 (DE-627)501466533 |0 (DE-576)298187914 |4 aut | |
| 245 | 1 | 2 | |a A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies |c Nina Hanke, Denise Türk, Dominik Selzer, Sabrina Wiebe, Éric Fernandez, Peter Stopfer, Valerie Nock and Thorsten Lehr |
| 264 | 1 | |c 16 June 2020 | |
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.10.2020 | ||
| 520 | |a The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work was to develop a mechanistic whole-body physiologically based pharmacokinetic (PBPK) model to investigate and predict DDIs with verapamil. The model was established in PK-Sim®, using 45 clinical studies (dosing range 0.1–250 mg), including literature as well as unpublished Boehringer Ingelheim data. The verapamil R- and S-enantiomers and their main metabolites R- and S-norverapamil are represented in the model. The processes implemented to describe the pharmacokinetics of verapamil and norverapamil include enantioselective plasma protein binding, enantioselective metabolism by CYP3A4, non-stereospecific Pgp transport, and passive glomerular filtration. To describe the auto-inhibitory and DDI potential, mechanism-based inactivation of CYP3A4 and non-competitive inhibition of Pgp by the verapamil and norverapamil enantiomers were incorporated based on in vitro literature. The resulting DDI performance was demonstrated by prediction of DDIs with midazolam, digoxin, rifampicin, and cimetidine, with 21/22 predicted DDI AUC ratios or Ctrough ratios within 1.5-fold of the observed values. The thoroughly built and qualified model will be freely available in the Open Systems Pharmacology model repository to support model-informed drug discovery and development. | ||
| 650 | 4 | |a cytochrome P450 3A4 (CYP3A4) | |
| 650 | 4 | |a drug-drug interactions (DDIs) | |
| 650 | 4 | |a mechanism-based inactivation (MBI) | |
| 650 | 4 | |a model-informed drug discovery and development (MID3) | |
| 650 | 4 | |a non-competitive inhibition | |
| 650 | 4 | |a norverapamil | |
| 650 | 4 | |a P-glycoprotein (Pgp) | |
| 650 | 4 | |a physiologically based pharmacokinetic (PBPK) modeling | |
| 650 | 4 | |a verapamil | |
| 700 | 1 | |a Türk, Denise |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Selzer, Dominik |d 1983- |e VerfasserIn |0 (DE-588)117079016X |0 (DE-627)104006728X |0 (DE-576)512647798 |4 aut | |
| 700 | 1 | |a Wiebe, Sabrina |e VerfasserIn |0 (DE-588)1219325988 |0 (DE-627)1735273597 |4 aut | |
| 700 | 1 | |a Fernandez, Éric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stopfer, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Nock, Valerie Christine |d 1984- |e VerfasserIn |0 (DE-588)1035743159 |0 (DE-627)749488999 |0 (DE-576)38349527X |4 aut | |
| 700 | 1 | |a Lehr, Thorsten |d 1977- |e VerfasserIn |0 (DE-588)132457830 |0 (DE-627)69060050X |0 (DE-576)299158802 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d Basel : MDPI, 2009 |g 12(2020,6) Artikel-Nummer 556, 19 Seiten |h Online-Ressource |w (DE-627)614096529 |w (DE-600)2527217-2 |w (DE-576)313958653 |x 1999-4923 |7 nnas |a A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:6 |g pages:556 |g extent:19 |a A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies |
| 856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics12060556 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/1999-4923/12/6/556 |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20201009 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1219325988 |a Wiebe, Sabrina |m 1219325988:Wiebe, Sabrina |d 50000 |e 50000PW1219325988 |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1735274143 |e 3774011214 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1735274143","language":["eng"],"note":["Gesehen am 09.10.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies","title_sort":"mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies"}],"person":[{"roleDisplay":"VerfasserIn","display":"Hanke, Nina","role":"aut","family":"Hanke","given":"Nina"},{"role":"aut","display":"Türk, Denise","roleDisplay":"VerfasserIn","given":"Denise","family":"Türk"},{"role":"aut","display":"Selzer, Dominik","roleDisplay":"VerfasserIn","given":"Dominik","family":"Selzer"},{"roleDisplay":"VerfasserIn","display":"Wiebe, Sabrina","role":"aut","family":"Wiebe","given":"Sabrina"},{"family":"Fernandez","given":"Éric","display":"Fernandez, Éric","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Stopfer, Peter","roleDisplay":"VerfasserIn","given":"Peter","family":"Stopfer"},{"family":"Nock","given":"Valerie Christine","display":"Nock, Valerie Christine","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Thorsten","family":"Lehr","role":"aut","display":"Lehr, Thorsten","roleDisplay":"VerfasserIn"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1999-4923"],"zdb":["2527217-2"],"eki":["614096529"]},"origin":[{"publisherPlace":"Basel","dateIssuedKey":"2009","publisher":"MDPI","dateIssuedDisp":"2009-"}],"name":{"displayForm":["Molecular Diversity Preservation International"]},"part":{"extent":"19","volume":"12","text":"12(2020,6) Artikel-Nummer 556, 19 Seiten","issue":"6","pages":"556","year":"2020"},"pubHistory":["1.2009 -"],"language":["eng"],"recId":"614096529","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 28.05.14"],"disp":"A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studiesPharmaceutics","title":[{"title":"Pharmaceutics","title_sort":"Pharmaceutics"}]}],"physDesc":[{"extent":"19 S."}],"id":{"eki":["1735274143"],"doi":["10.3390/pharmaceutics12060556"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"16 June 2020"}],"name":{"displayForm":["Nina Hanke, Denise Türk, Dominik Selzer, Sabrina Wiebe, Éric Fernandez, Peter Stopfer, Valerie Nock and Thorsten Lehr"]}} | ||
| SRT | |a HANKENINATMECHANISTI1620 | ||